Jin Rong Jie·2025-08-05 08:53Group 1 - The Shanghai Composite Index rose by 0.96%, closing at 3617.6 points, while the Hang Seng Index increased by 0.68%, closing at 24902.53 points [1] - The premium of Haiprui's A-shares over H-shares reached 125.21%, ranking 16th among AH shares [1] - Haiprui's A-shares closed at 13.26 yuan, with a gain of 0.68%, and H-shares closed at 6.43 HKD, up by 3.38% [1] Group 2 - Shenzhen Haiprui Pharmaceutical Group Co., Ltd. was established in 1998 and is a leading multinational pharmaceutical company with A+H dual financing platforms [1] - The company's main business covers the entire heparin industry chain, biopharmaceutical CDMO, and the investment, development, and commercialization of innovative drugs [1] - Haiprui's three business segments are synergistic, driven by unmet clinical needs, aiming to provide high-quality, safe, and effective drugs and services to global patients [1]